Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 55.40 TWD
Change Today -0.80 / -1.42%
Volume 166.0K
As of 2:32 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

orient europharma co ltd (4120) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/4/14 - 85.50
52 Week Low
07/31/15 - 55.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ORIENT EUROPHARMA CO LTD (4120)

Related News

No related news articles were found.

orient europharma co ltd (4120) Related Businessweek News

No Related Businessweek News Found

orient europharma co ltd (4120) Details

Orient Europharma Co., Ltd. manufactures and distributes pharmaceuticals in Taiwan and internationally. The company offers general pharmaceutical products comprising anti-hypotensive, cardiovascular, diabetic, asthma inhalant, andropausal, anti-Parkinson, and immunosuppressant, as well as endocrinology, orthopedic, and immunology products; and anti-cancer and anti-hemophilic drugs. It also distributes cosmeceutical and anti-aging products comprising skin irritation and skin protection products; hair shampoo and treatment care products; cosmetics for sensitive skin; skincare oil products; emergency contraception products; and products for facial augmentation, lip enlargement, and skin refinement. In addition, the company distributes nutrition and baby care products, such as infant/children cow milk powder, goat milk powder, baby food and nutritional supplements, and hydrolyzed protein and acidified formula products under the Karihome, Babecare, and Ostricare brand names. Further, it provides healthcare supplements that comprise spring water oral care products under the Buccotherm name; family nutritional supplements under the Carginine name; and Ostricare (Adult) products. Additionally, the company is engaged in the research and development of Multikine, a novel immunotherapy drug for the head and neck cancer that is in Phase III pivotal clinical study; NC-6004, a micelle chemotherapeutic drug, which is in Phase III clinical study; NOX-100, a chemical entity drug for preventing intradialytic hypotension and IDH during hemodialysis that is in Phase II clinical study; and ASC-J9, which is a molecular chemical entity drug for the enhancement of androgen receptor degradation that is in Phase IIb clinical study. Orient Europharma Co., Ltd. was founded in 1982 and is based in Taipei, Taiwan.

Founded in 1982

orient europharma co ltd (4120) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

orient europharma co ltd (4120) Key Developments

Orient Europharma Co., Ltd., Annual General Meeting, Jun 30, 2015

Orient Europharma Co., Ltd., Annual General Meeting, Jun 30, 2015.

Toray Industries, Inc. Signs Licensing Agreement with Orient EuroPharma Co., Ltd. for Antipruritic Drug TRK-820

Toray Industries Inc. and Orient EuroPharma Co., Ltd. have signed a licensing agreement for the antipruritic drug TRK-820 developed by Toray for treating hemodialysis pruritus, in Taiwan. The agreement enables OEP to develop and market the product exclusively in Taiwan. TRK-820 is a highly selective kappa opioid receptor agonist and it has been sold as REMITCH CAPSULES 2.5 µg for treating hemodialysis-related uremic pruritus in Japan since March 2009. By licensing in TRK-820, OEP enhances its development pipeline in the renal disease area, which it is focusing on, and will actively drive forward its clinical development to bring a new therapeutic method to the hemodialysis patients suffering from pruritus in Taiwan as early as possible. Toray hopes to make contributions to relieve the pruritus of hemodialysis patients in Taiwan through this alliance.

Orient Europharma Co., Ltd. and Debiopharm Group Announce the Signature of Distribution Agreement for the Commercialization and Promotion of Pamorelin(R) in South East Asia

Orient Europharma Co., Ltd. and Debiopharm announced the signature of a distribution agreement for the commercialization and promotion of Pamorelin(R) in South East Asia. Orient EuroPharma and Debiopharm announce the launch of Pamorelin(R) in Singapore for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer. Under the terms of the agreement, Orient EuroPharma acquires exclusive marketing and sales rights for Pamorelin(R) in Singapore, its first launch territory. The product is exported in finished bulk from Debiopharm Research and Manufacturing SA to Orient EuroPharma. Pamorelin(R) will be made available primarily to urologists and oncologists across Singapore.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4120:TT 55.40 TWD -0.80

4120 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4120.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4120 Industry Range
Price/Earnings 18.8x
Price/Sales 0.9x
Price/Book 1.6x
Price/Cash Flow 18.8x
TEV/Sales 0.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORIENT EUROPHARMA CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at